|1.||Long, Carole A: 19 articles (01/2014 - 01/2002)|
|2.||Holder, Anthony A: 18 articles (01/2014 - 09/2002)|
|3.||Angov, Evelina: 13 articles (01/2015 - 11/2003)|
|4.||Chauhan, Virander S: 10 articles (03/2015 - 03/2004)|
|5.||Langhorne, Jean: 10 articles (12/2014 - 03/2004)|
|6.||Moormann, Ann M: 10 articles (07/2013 - 07/2004)|
|7.||Kazura, James W: 10 articles (07/2013 - 01/2002)|
|8.||Tanabe, Kazuyuki: 9 articles (06/2015 - 12/2002)|
|9.||Martin, Laura B: 9 articles (01/2010 - 10/2003)|
|10.||Hill, Adrian V S: 8 articles (04/2014 - 03/2002)|
10/01/2010 - "Although immunity against MSP1 alone will not confer protection against malaria, demonstrating a relative and sustained increase in T-cell immunity to MSP1 after vaccination would be a reasonable measurement of vaccine responsiveness."
11/01/2005 - "Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit."
04/15/2009 - "Our findings highlight a new mechanism involving MSP1 in the protection against malaria."
01/01/2014 - "These results suggest that sero-epidemiological studies employing MSP-1 (ICB910)-ELISA may be helpful in estimating the prevalence of malaria in certain geographic areas. "
04/15/2005 - "Protection against malaria induced by chirally modified Plasmodium falciparum's MSP-1 42 pseudopeptides."
12/01/2002 - "Collectively, these experiments show that multiantigen combinations offer enhanced levels of protection against asexual stage infection and suggest that combinations of MSP1, MSP4, and MSP5 should be evaluated further for use in humans."
03/01/2002 - "The efficacy of the MSP3 vaccination appeared to be comparable to that of MSP1(42), a leading asexual vaccine candidate, in response to which 2 monkeys experienced acute infections. "
01/01/1999 - "Partial protection against Plasmodium vivax blood-stage infection in Saimiri monkeys by immunization with a recombinant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuvant."
07/01/1998 - "Immunity to MSP-1 has been implicated in protection against infection in animal models. "
04/01/2015 - "This study aimed to (1) determine the prevalence of the msp-1 and msp-2 allelic familiesand (2) identify the multiplicity of infection (MOI) in P. "
12/01/2002 - "Combined immunization with MSP1(19) and yMSP4/5, a product characterized by lower protective efficacy, also greatly enhanced protection by reducing peak parasitemias and increasing the numbers of survivors. "
12/01/2002 - "Many mice immunized with the MSP4/5 plus MSP1(19) combination did not develop detectable parasitemia after challenge. "
10/01/1997 - "We optimized a vaccine protocol using the MSP1(19) fragment of Plasmodium yoelii expressed in Saccharomyces cerevisiae, such that following exposure of mice to parasites, they remained undetectable in peripheral blood, whereas control animals all died at very high parasitemia within 10 days. "
07/01/2008 - "No association was found between allelic number of msp-1 or msp-2 and season of travel, absence of antimalarial prophylaxis, length of stay or blood parasitemia. "
06/20/2003 - "Mice immunized with MSP1(19) adjuvanted with Montanide ISA720 showed delayed patent parasitemia with all mice ultimately succumbing to infection. "
|4.||Falciparum Malaria (Plasmodium falciparum Malaria)
12/09/2008 - "A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria."
08/01/2015 - "[Analysis of MSP1 Allelotypes in Imported Cases of Plasmodium falciparum Malaria from Africa]."
04/01/2015 - "MAD 20 alleles of merozoite surface protein-1 (msp-1) are associated with severe Plasmodium falciparum malaria in Pakistan."
01/01/2015 - "Correction: Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175."
01/01/2015 - "Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175."
|5.||Bites and Stings (Sting)
|2.||Merozoite Surface Protein 1 (MSA1)
|5.||Interferon-gamma (Interferon, gamma)
|6.||Immunoglobulin G (IgG)
|7.||Membrane Proteins (Integral Membrane Proteins)
|9.||Proteins (Proteins, Gene)
|1.||Hormone Replacement Therapy (Therapy, Hormone Replacement)
|3.||Length of Stay